Stay updated on Empagliflozin in Heart Failure Clinical Trial
Sign up to get notified when there's something new on the Empagliflozin in Heart Failure Clinical Trial page.
Latest updates to the Empagliflozin in Heart Failure Clinical Trial page
- Check6 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4; no observable changes to study details or layout.SummaryDifference0.1%
- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedAdded a Locations section with the Connecticut site for the EMPA trial and removed the HHS Vulnerability Disclosure footer link and the older Connecticut Locations listing.SummaryDifference0.2%
- Check56 days agoChange DetectedThe Publications note was updated to indicate PubMed auto-filling, and the page revision was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%
- Check63 days agoChange DetectedThe notice about government funding-related data delays and operating status has been removed from the page. This removes guidance on data timeliness during funding lapses.SummaryDifference0.4%
- Check77 days agoChange DetectedThe new screenshot shows only visual/layout adjustments without changes to core study content, eligibility criteria, enrollment, or results; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check106 days agoChange DetectedSummary: The page now displays a funding-status notice and announces a major version upgrade to v3.2.0, replacing the previous v3.1.0.SummaryDifference4%
Stay in the know with updates to Empagliflozin in Heart Failure Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Empagliflozin in Heart Failure Clinical Trial page.